
S&P/TSX composite cruises to record close on rise in energy stocks
Canada's main stock index rode energy stocks to a record close Monday, despite a cautious day that followed a month of major gains and a weekend checkered with angst over higher steel tariffs and developments in Ukraine and the Middle East.
'There was actually a fair bit of nervousness coming into today on the weekend, with some of the Trump tariff headlines that came out after the close on Friday and geopolitical tensions again with Russia and Ukraine,' said Greg Taylor, chief investment officer at PenderFund Capital Management.
But the S&P/TSX composite index climbed 213.91 points to 26,388.96, its highest level ever at day's end.
In New York, the Dow Jones industrial average overcame an initial drop to rise 35.41 points to 42,305.48. The S&P 500 index inched up 24.25 points to 5,935.94, while the Nasdaq composite increased 128.85 points to 19,242.61.
'In Canada it's more of a cautious tone, and I think the fact that we're higher — led by the commodities — is probably a decent positive, especially after such a big move that we had in markets in May,' Taylor said.
The TSX posted its largest monthly gain since November in May, rising 5.56 per cent.
That trajectory continued Monday, driven by gold and oil shares.
Energy stocks flowed upward after OPEC-plus countries announced Saturday they would ramp up oil production less than some had feared.
Meanwhile, Ukrainian attacks in Russia over the weekend raised uncertainty about the flow of oil and gas around the world, as did Iran's criticism of a report that revealed its growing stockpiles of enriched uranium.
'We're also seeing a bit of concern with the wildfires out west and whether that's going to take even more supply off the board,' Taylor said, pointing to blazes raging across the Prairies that have forced producers to remove non-essential staff and shut output.
On the metals front, Agnico Eagle Mines Ltd., Barrick Mining Corp. and Kinross Gold Corp. placed among the mining outfits whose shares rose by between 5.2 and 6.3 per cent on Monday.
Taylor said geopolitical tension and a weaker U.S. dollar help explain their popularity, with the price of gold often seen as an inverse barometer of economic anxiety.
After markets closed Friday, U.S. President Donald Trump announced he would double the tariffs on steel and aluminum imports to 50 per cent this Wednesday. But the TSX industrials index ticked down only slightly.
Taylor said markets now take the president's pronouncements with a grain of another commodity: salt.
'As much as no one likes to say it out loud, Trump has a history of walking back on a lot of these announcements that just seem to be thrown out there as trial balloons as much as anything else,' Taylor said.
'This might actually not come to pass.'
This week, investors will be watching whether the Bank of Canada will cut interest rates on Wednesday.
Market watchers will also be on the lookout for national employment figures slated to drop on June 6.
'There has been a bit of a concern around the health of the economy and whether we are going to start to see a slowdown and on the verge of looking at a recession, and that payroll number is probably going to be a good indicator,' Taylor said.
The Canadian dollar traded for 72.96 cents US compared with 72.68 cents US on Friday.
The July crude oil contract was up US$1.73 at US$62.52 per barrel and the July natural gas contract was up 24 cents US at US$3.69 per mmBTU.
The August gold contract was up US$81.80 at US$3,397.20 an ounce and the July copper contract was up 18 cents US at US$4.86 a pound.
This report by The Canadian Press was first published June 2, 2025.
Companies in this story: (TSX: GSPTSE, TSX: CADUSD)
— With files from The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
19 minutes ago
- Associated Press
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ('HCWB' or 'HCW Biologics'), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended. In addition to the $7.0 million upfront payment, HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. Furthermore, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering. Dr. Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics, stated, 'We have a strategic focus to establish commercialization partnerships for our novel protein and antibody therapies with innovative leaders in the immunotherapy field. HCW11-006, the product candidate subject to the license with WY Biotech, combines several different immune functional domains on HCW Biologics' TRBC drug discovery and development platform as part of a group of compounds characterized as Multi-Functional Immune Cell Stimulators. Preclinical studies demonstrated that HCW11-006 is highly effective at inducing anti-tumor CD8+ T cell and NK cell responses without triggering unwanted side effects in relevant solid tumor animal models.' About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and possibly extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-018 and HCW11-040. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at Forward Looking Statements: Statements in this press release contain 'forward-looking statements' that are subject to substantial risks and uncertainties. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'expect,' 'believe,' 'will,' 'may,' 'should,' 'estimate,' 'project,' 'outlook,' 'forecast' or other similar words and include, the potential for a future transaction and sharing proceeds therefrom; the ability for HCWB to recapture and commercialize rights in certain territories; the ability of HCW11-006 to induce anti-tumor CD8+ T cell and NK cell responses; . Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled 'Risk Factors' in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the 'SEC') on March 28, 2025, the latest Form 10-Q filed with the SEC on May 15, 2025 and in other filings filed from time to time with the SEC. Company Contact: Lee Flowers Senior Vice President, Business Development HCW Biologics Inc. [email protected]

Associated Press
19 minutes ago
- Associated Press
NXT Energy Solutions Shares CEO's AGM Comments
CALGARY, AB / ACCESS Newswire / June 4, 2025 / NXT Energy Solutions Inc. ('NXT' or the 'Company') (TSX:SFD)(OTCQB:NSFDF) is pleased to share the following remarks that were delivered by Bruce G. Wilcox, NXT's Chief Executive Officer, during the annual meeting of shareholders held on June 2, 2025. 'Welcome to all present, including our shareholders, staff and service providers. We also welcome our directors participating by phone, including Jeffrey Tilson, Gerry Sheehan, and Theodore Patsellis. As I think most of you know, I spent nearly four decades as an equity analyst, portfolio manager and CEO of one of the first long/short equity investment firms in New York. What I learnt from this experience is that the primary job of management of a public company is to operate the business in a way that increases the value per share. A secondary responsibility is to convey to the public the steps we are taking to fulfill that primary responsibility so that the market price per share approaches value per share. The means to increasing value per share for NXT is to keep our calendar as full as our staff and aircraft can accommodate. In 2025 we have a nearly completely full calendar and we are building out our pipeline for 2026. Shortly after my appointment as Interim CEO in 2023 I articulated an internal theme of 'Frequency, Adjacency and Repeatability'. In other words, keep the plane and staff busily engaged, exploit opportunities with operators geographically adjacent to where we perform surveys and develop more consistent repeat business. I am happy to say that we are making significant progress on all of these fronts. We are undertaking deeper quantitative analysis of our interpretation methods and delivery mechanisms which we hope will speed up the interpretation and delivery of our final survey reporting and make the data more accessible and 'user friendly' for our clients. It is early days and we will communicate progress as this analysis proceeds. We have rehired a former staff member to increase our interpretation capability, we will continue to build out our sensor inventory and streamline our Standard Operating Procedures. All of this gives us the tools to continue to build our annual revenue and earnings potential. In terms of conveying our progress to the public, we have been as thorough as we can be in communicating our orderbook as it is confirmed. One of the limiting factors in affecting our disclosure is that the majority of our clients have competitive reasons not to publicize their data acquisition plans while a survey is in process. However, since the cycle time of our contracts from data acquisition to final report delivery and integration is fairly short, typically four to six months, the results are captured quite quickly in our financial reporting. We have been asked from time to time about providing guidance and while I expect that we will ultimately get there, I believe we need to make sure our pipeline and order book are stable. What a difference two years make! Along the way we faced very challenging financial pressures, and we are deeply appreciative of the support we received from existing shareholders and our Strategic Partner's leader, Dr. Daere Akobo. Our staff have executed superbly in some very trying times. With our recent earnings and the conversion of debentures by our Strategic Partner, our working capital and overall balance sheet has substantially improved. Looking forward, I caution investors against expecting quarter over quarter revenue advances but do believe we can and will aspire to show annual progress. As we grow, and only when it makes financial sense, we will begin the early stages of evaluating the need for additional resources like an additional aircraft and staff to support our expanding business. Thank you again to everyone for attending today.' About NXT Energy Solutions Inc. NXT Energy Solutions Inc. is a Calgary-based technology company whose proprietary airborne SFD® survey system, applied in numerous basins around the world, uses the principles of quantum mechanics to infer stress anomalies of exploration interest. The method can be used both onshore and offshore to remotely identify areas conducive to fluid entrapment in order to recommend areas with commercial hydrocarbon and/or geothermal potential. The SFD® survey system enables our clients to focus their exploration decisions concerning land commitments, data acquisition expenditures and prospect prioritization on areas with the greatest potential. SFD® is environmentally friendly and unaffected by ground security issues or difficult terrain and is the registered trademark of NXT Energy Solutions Inc. NXT Energy Solutions Inc. provides its clients with an effective and reliable method to reduce time, costs, and risks related to exploration. Contact Information For investor and media inquiries please contact: Forward-Looking Statements Certain information provided in this press release may constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information typically contains statements with words such as 'anticipate', 'believe', 'estimate', 'will', 'expect', 'plan', 'schedule', 'intend', 'propose' or similar words suggesting future outcomes or an outlook. Forward-looking information in this press release includes, but is not limited to, information regarding: the timing of the booking of SFD® surveys for 2025 and 2026 and the effect the booking have on the value and market price per share, progress achieved by following the internal theme of 'Frequency, Adjacency and Repeatability', that deeper quantitative analysis of our interpretation methods and delivery mechanisms will speed up interpretation and delivery of our final survey reporting, make the data more accessible and 'user friendly' for our clients and build our annual revenue and earnings potential, and that the conversion of debentures will substantially improve our working capital and overall balance sheet. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Additional risk factors facing the Company are described in its most recent Annual Information Form for the year ended December 31, 2024 and MD&A for the three months ended March 31, 2025, which have been filed electronically by means of the System for Electronic Document Analysis and Retrieval ('SEDAR+") located at The forward-looking statements contained in this press release are made as of the date hereof, and except as may be required by applicable securities laws, the Company assumes no obligation to update publicly or revise any forward-looking statements made herein or otherwise, whether as a result of new information, future events or otherwise. SOURCE: NXT Energy Solutions, Inc. press release


New York Post
19 minutes ago
- New York Post
How Steelers responded to fans upset by Mason Rudolph attending Trump rally
The Steelers responded to angry fans after the team received complaints about quarterback Mason Rudolph and special teams captain Miles Killebrew attending a rally held by President Donald Trump in West Mifflin, Penn., last week. The appearance led to a swift reaction from fans and season ticket holders, and prompted the organization to send an email explaining that players, both former and current, 'make their own individual decisions,' the Pittsburgh Post-Gazette reported. Trump had been in Pennsylvania for a rally at the U.S. Steel plant in West Mifflin, and former Steelers great Rocky Bleier also joined the trio on stage. Advertisement Mason Rudolph speaking alongside President Trump at a May 2025 event. AP 'We appreciate you taking the time to share your thoughts with us. As valued fans, your voice is an essential part of what makes our Steelers community and fan base so strong,' the email said. 'We understand that a recent rally in Pittsburgh has generated a range of reactions from our fan base. Our alumni and current players make their own individual decisions that reflect their views, and they do not necessarily represent the view of the entire Pittsburgh Steelers organization. 'Thank you again for sharing your thoughts. We appreciate your passion and your continued support of the team.' Advertisement Despite the Rooney family, which owns the Steelers, being strong Democratic supporters, several former Steelers players have appeared at rallies for the President. In October, Antonio Brown and Le'Veon Bell were on hand at a Trump Rally in Latrobe, Penn. Bleier called Trump a 'Hall of Fame President' when he presented him with a custom No. 47 jersey during Friday's rally and declared him an 'honorary Steeler.' Advertisement President Trump holds a steelers jersey at a May 2025 event. AP Killebrew said on stage, 'God bless you, President Trump,' when invited to speak by the President. Trump invited all three Steelers to the stage and predicted Rudolph would be 'the guy' for Pittsburgh while the team waits for Aaron Rodgers to make a decision.